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Abstract 
Purpose: There is a significant difference in the mean tumor size between very young breast cancer patients and 
their elder counterparts. A simple comparison may show obvious prognostic differences. We investigated the prog-
nostic impact of age by reducing the influence of the tumor size, which is thought to be a confounding factor.
Patients and methods: We investigated 1,880 consecutive pT1-4N0-3M0 breast cancer patients treated at less than 
45 years of age between 1986 and 2002 and conducted a case–control study of breast cancer subjects less than 
30 years of age. Each patient (Younger than 30) was matched with a corresponding control subject (Elder counter-
part) based on an age 15 years above the patient’s age, a similar tumor size and a status of being within 1 year after 
surgery. In addition, we assessed 47 patients with pregnancy-associated breast cancer (PABC). The levels of hormone 
receptors were measured using an enzyme immunoassay (EIA), and receptor-positive cases were divided into “weakly” 
and “strongly” positive groups based on the median value. Years from the last childbirth (YFLC) was categorized as 
“recent” and “past” at the time point of 8 years.
Results: There were fewer past YFLC cases, more partial mastectomy cases, a higher rate of scirrhous carcinoma or 
solid-tubular carcinoma in the Younger than 30 group than in the Elder counterpart group. The rates of a PgR-nega-
tive status in the Younger than 30 and Elder counterpart groups were 45.1 and 29.9%, respectively, As for the relation-
ship between the PgR-negative rate and YFLC, the rates of a PgR-negative status in the past YFLC, nulliparous, recent 
YFLC and PABC groups were 31.9, 37.7, 44.4 and 65.7%, respectively. On the other hand, the rates of strongly positive 
cases were 42.6, 30.2, 22.2 and 8.6%, respectively. The 10-year recurrence-free survival rates in the Younger than 30, 
Elder counterpart and PABC groups were 61.7, 65.6 and 54.1%, respectively. The differences between the groups 
were not significant. In a multivariate analysis, independent prognostic facers included the number of lymph node 
metastases (4–9, HR:3.388, 95% CI 1.363–8.425, p = 0.0086, over 10, HR: 6.714, 2.033–22.177, p = 0.0018), solid-tubular 
carcinoma (HR 3.348, 1.352–8.292, p = 0.0090), scirrhous carcinoma (HR 2.294, 1.013–5.197, p = 0.0465) and past YFLC 
(HR 0.422, 0.186–0.956, p = 0.0387). An age younger than 30 was not found to be an independent prognostic factor.
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Open Access
*Correspondence:  m-makita@nms.ac.jp 
7 Department of Breast Surgery, Nippon Medical School Musashi 
Kosugi Hospital, 1-396 Kosugi-machi, Nakahara-ku, Kawasaki, Kanagawa 
211-8533, Japan
Full list of author information is available at the end of the article
Page 2 of 10Makita et al. SpringerPlus  (2015) 4:365 
Background
The poor prognosis of very young breast cancer patients 
has been reported to be caused partly by a delay in diag-
nosis (Maggard et  al. 2003; Kataoka et  al. 2014), and 
results are inconsistent as to whether age is an inde-
pendent prognostic factor (Cancello et  al. 2010; Crowe 
et al. 1994). On the other hand, some reports have found 
that the number of years from the last childbirth influ-
ences the prognosis of patients with breast cancer as 
well as pregnancy-associated breast cancer (PABC) 
(Mohle-Boetani et al. 1988; Kroman et al. 1997; Kroman 
and Mouridsen 2003; Nagatsuma et  al. 2013). It is diffi-
cult to study the prognosis of very young breast cancer 
patients due to the paucity of patients and larger tumors. 
There is a significant difference in the mean tumor size 
between very young breast cancer patients and their 
elder counterparts. A simple comparison may show obvi-
ous prognostic differences. Therefore, it should be proven 
whether very young breast cancer patients have a poorer 
prognosis than their elder counterparts for tumors in the 
same stage.
Is the solution to improving the worse prognosis of 
very young breast cancer patients early detection only? 
Pregnancy experienced at a young age influences the 
prognosis of breast cancer, and the hormonal milieu of 
very young women differs from that observed in elder 
women, even those who are premenopausal. Some 
patients with a family history of breast cancer are apt to 
develop early-onset disease. It is therefore valuable to 
investigate important prognostic factors other than the 
tumor size when considering treatment for very young 
breast cancer patients. Hence, we investigated the prog-
nostic impact of age by reducing the impact of the tumor 
size, which is thought to be a confounding factor.
Patients and methods
A total of 9,713 consecutive patients were surgically 
treated for primary breast cancer between 1986 and 
2002 at the Cancer Institute Hospital, Tokyo, Japan. The 
patients included in this study comprised only those who 
had been treated at less than 45 years of age at the time 
of surgery for breast cancer. Patients with distant metas-
tases and noninvasive breast carcinoma, bilateral second 
breast cancer or synchronous bilateral breast cancer were 
excluded. In total, 1,880 individuals met the eligibility 
criteria for this study. We conducted a case–control study 
of very young (<30  years of age) breast cancer patients. 
Each very young breast cancer patient (younger than 30) 
was matched with a corresponding control patient (elder 
counterpart) in accordance with the following crite-
ria: (1) an age 15 older than the patient’s age (e.g., if the 
patient was 23 y.o., the control was 38 y.o.), (2) a similar 
tumor size (pathological or clinical) and (3) a similar cal-
endar year of breast surgery (within 1 year). We decided 
15-years older cohort as Elder counterpart, because the 
difference of recurrence-free survival (RFS) between 
15-years older cohort and the Younger than 30 was 
the largest, after comparing four RFS curves of 5-, 10-, 
15-years older cohort and the Younger than 30. In addi-
tion, we assessed 47 patients with pregnancy-associated 
breast cancer (PABC: defined during pregnancy or within 
1  year from childbirth) within the same study period. 
This study was approved by Institutional Review Board 
of Cancer Institute Hospital of Japanese Foundation for 
Cancer Research (2014-1115). The concentrations of hor-
mone receptor were measured using an enzyme immu-
noassay (EIA). An estrogen receptor (ER)-positive status 
was defined as ≥5  fmol/mg and a progesterone recep-
tor (PgR)-positive status was defined as ≥10  fmol/mg. 
Receptor-positive cases were divided into “weakly” and 
“strongly” positive groups based on the median value 
(the median ER and PgR values were 21 and 95, respec-
tively). Years from the last childbirth (YFLC) was clas-
sified as “recent” or “past” at the time point of 8  years, 
because it was calculated as the cutoff point according 
to the receiver-operator curve (ROC) between the YFLC 
and recurrence/deaths groups using 119 parous cases. 
Because seven YFLC was the longest in the Younger than 
30, it was meaningless to define 9 years and over as the 
cutoff point. And the correlation between recurrence/
deaths and YFLC was not significant at the time point of 
5 years, but significant at 8 years.
The following factors were evaluated: calendar year 
of surgery, family history of breast cancer, YFLC, tumor 
size (pathological), lymph node metastases, histologi-
cal type classified according to the Japanese Breast Can-
cer Society: General Rules for Clinical and Pathological 
Recording of Breast Cancer guidelines (Japanese Breast 
Cancer Society 1989), extent of tumor invasion (Japanese 
Breast Cancer Society 1989), lymphovascular invasion, 
Conclusions: The prognosis of the very young women was the same as their elder counterparts with a matched 
tumor size, and age was not identified to be an independent prognostic factor according to the multivariate analysis. 
Recent childbirth probably influences the prognosis of patients younger than 30 years of age with breast cancer by 
lowering hormonal sensitivity.
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hormone receptor status, type of surgery and adjuvant 
treatment. We reviewed the patients’ charts retrospec-
tively. All types of recurrence and death were considered 
as events, and RFS was calculated based on the Kaplan–
Meier method. The onset of second breast cancer was 
considered to be censored in the heterochronous bilat-
eral breast cancer cases. The univariate statistical analysis 
was performed using the Chi square test, Mann–Whit-
ney U-test and log-rank test. The multivariate analysis 
was performed using Cox’s proportional hazard model. A 
p value of <0.05 was defined as significant. The computer 
software program, “Stat View for Windows version 4.54 
“(Abacus Concepts, Inc., Berkley, CA, USA), was used for 
all analyses. The median follow-up time was 10.8 years.
Results
The number of events in the Younger than 30 and Elder 
counterpart groups was 37 and 30, respectively. Except 
for one death without disease, all events were episodes of 
recurrence. The number of local and/or regional recur-
rence cases in the Younger than 30 and Elder counterpart 
groups was 15 and 13, respectively. The rates of distant 
metastases only per all recurrent cases were the same 
between the groups (younger than 30: 21/37  =  56.8%; 
elder counterpart: 17/30 =  56.7%). The number of het-
erochronous bilateral breast cancer cases was seven, all 
of which belonged to the younger than 30 group.
As for the case distribution, there were fewer parous 
cases, fewer past YFLC cases, more partial mastectomy 
cases, and higher rates of scirrhous carcinoma and solid-
tubular carcinoma in the Younger than 30 group than in 
the Elder counterpart group (Table 1). The mean age in 
the Younger than 30, Elder counterpart and PABC groups 
was 27.1, 42.1 and 35.4 years, respectively. There were no 
differences between the two groups in terms of family 
history. Regarding hereditary breast and ovarian cancer 
(HBOC), there were no patients with BRCA mutations. 
Only two patients underwent genetic tests, and only one 
patient in the Younger than 30 group had a p53 mutation 
and was diagnosed with Li-Fraumeni syndrome (Li and 
Fraumeni 1969).
The rates of an ER-negative status in the Younger than 
30 and Elder counterpart groups were 57.4% (31/54) 
and 44.8% (30/67), respectively, while the rates of a PgR-
negative status in the Younger than 30 and Elder coun-
terpart groups were 45.1% (23/51) and 29.9% (20/67), 
respectively. As for the relationship between the PgR-
negative rate and YFLC, the rates of a PgR-negative status 
in the past YFLC, nulliparous, recent YFLC and PABC 
groups were 31.9, 37.7, 44.4 and 65.7%, respectively. On 
the other hand, the rates of strongly positive findings 
(>95  fmol/mg) were 42.6, 30.2, 22.2 and 8.6%, respec-
tively (Figure  1). More recent childbirth was correlated 
with lower hormonal sensitivity. The mean ER values on 
EIA in the Younger than 30, Elder counterpart and PABC 
groups were 10.9, 18.9 and 4.2 fmol/mg, respectively and 
the mean PgR values in the Younger than 30, Elder coun-
terpart and PABC groups were 83.6, 177.2 and 21.4 fmol/
mg, respectively; the concentrations of PgR on EIA were 
significantly lower in the Younger than 30 group than 
in the Elder counterpart group (Mann–Whitney U test 
p = 0.0232, Figure 2).
The RFS rate was 61.7% at 10 years and 45% at 15 years 
in the Younger than 30 group. On the other hand, these 
rates in the Elderly counterpart group were 65.6 and 
63.7%, respectively (p = 0.3865, Log-rank test, Figure 3) 
and those in the PABC group were 54.1 and 49.6%, 
respectively. Although the RFS curve in the younger than 
30 group gradually decreased after 10  years, the differ-
ence between the groups was not significant.
The results of the univariate analysis of each factor 
among the total 160 cases in the younger than 30 and 
Elderly counterpart groups are demonstrated in Table 2. 
The 10-year RFS in the past YFLC group was 72%, which 
was significantly higher than that seen in the nulliparous/
recent YFLC group (59.3%, p = 0.0399). The multivariate 
analysis of significant factors identified in the univariate 
analyses (tumor size, lymph node metastases, histologi-
cal type, extent of tumor invasion, lymphovascular inva-
sion, adjuvant chemotherapy and PgR), in addition to age 
and YFLC, showed the independent prognostic facers to 
be the number of lymph node metastases (4–9, HR:3.388, 
95% CI 1.363–8.425, p  =  0.0086, over 10, HR: 6.714, 
2.033–22.177, p = 0.0018), solid-tubular carcinoma (HR 
3.348, 1.352–8.292, p  =  0.0090), scirrhous carcinoma 
(HR 2.294, 1.013–5.197, p = 0.0465) and past YFLC (HR 
0.422, 0.186–0.956, p = 0.0387. Table 2). An age younger 
than 30 years was not found to be an independent prog-
nostic factor.
Discussion
The frequency of breast cancers at less than 30  years 
of age is approximately 1% of all breast cancers, and 
a younger age has been reported to have a worse prog-
nosis among premenopausal as well as all breast cancer 
patients (Maggard et al. 2003; Cancello et al. 2010). How-
ever, the recent recommendation of St. Gallen excluded a 
younger age as prognostic factor (Glick et al. 1992; Gol-
dhirsch et  al. 2001, 2009; Colleoni et  al. 2006), and we 
previously reported that the prognosis of PABC is cor-
related with a younger age (Makita et  al. 2007). In this 
study, a younger age was not found to be an independent 
prognostic factor, although recent childbirth probably 
influenced the prognosis of the younger than 30 breast 
cancer patients by lowering their hormonal sensitivity. In 
addition, the prognosis of PABC and very young breast 
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Table 1 Patient characteristics
Factors Case (younger than 30) Control (elder counterpart) Chi square test PABC 47 cases
Cases (%) Cases (%) P value Cases (%)
Calendar year of surgery
 1986–1995 40 (50.0%) 40 (50.0%) >0.9999 25 (53.2%)
 1996–2002 40 (50.0%) 40 (50.0%) 22 (46.8%)
Age at surgery, years old
 <35 80 (100.0%) 1 (1.3%) <0.0001 20 (42.6%)
 ≥35 0 (0.0%) 79 (98.8%) 27 (57.4%)
Family history of breast cancer
 None 69 (86.3%) 69 (86.3%) >0.9999 40 (85.1%)
 Positive 11 (13.8%) 11 (13.8%) 7 (14.9%)
Years from the last childbirth (YFLC)
 Nulliparous 68 (85.0%) 16 (20.0%) <0.0001 4 (8.5%)
 Recent (<8) 12 (15.0%) 8 (10.0%) 43 (91.5%)
 Past (≥8) 0 (0.0%) 56 (70.0%) 0 (0.0%)
Tumor size, cm (Pathological)
 ≤2 20 (25.0%) 23 (28.8%) 0.1826 13 (27.7%)
 2.1–5 28 (35.0%) 42 (52.5%) 21 (44.7%)
 >5 11 (13.8%) 6 (7.5%) 5 (10.6%)
The number of metastatic lymph nodes
 None 40 (50.0%) 38 (47.5%) 0.3553 14 (29.8%)
 1–3 24 (30.0%) 23 (28.8%) 15 (31.9%)
 4–9 6 (7.5%) 13 (16.3%) 11 (23.4%)
 10– 9 (11.3%) 6 (7.5%) 7 (14.9%)
Histological type
 Papillotubular carcinoma 18 (22.5%) 24 (30.0%) 0.1003 9 (19.1%)
 Sollid-tubular carcinoma 28 (35.0%) 16 (20.0%) 20 (42.6%)
 Scirrhous carcinoma 29 (36.3%) 27 (33.8%) 13 (27.7%)
 Special types 4 (5.0%) 10 (12.5%) 5 (10.6%)
 Unilateral double cancer 1 (1.3%) 3 (3.8%) 0 (0.0%)
Extent of tumor invasion (histological)
 Localized within mammary gland 29 (36.3%) 23 (28.8%) 0.4486 22 (46.8%)
 Invading the extramammary fat tissue 47 (58.8%) 50 (62.5%) 21 (44.7%)
 Invading the skin and/or muscle 4 (5.0%) 7 (8.8%) 4 (8.5%)
Lymphovascular invasion
 Absent 45 (56.3%) 53(66.3%) 0.2559 24 (51.1%)
 Present 35 (43.8%) 27(33.8%) 23 (48.9%)
Estrogen receptor(EIA), fmol/mg
 <5 (negative) 31 (38.8%) 30 (37.5%) 0.2563 31 (66.0%)
 5–21 (weakly positive) 14 (17.5%) 18 (22.5%) 2 (4.3%)
 22– (strongly positive) 9 (11.3%) 19 (23.8%) 4 (8.5%)
 Not performed 26 (32.5%) 13 (16.3%) 10 (21.3%)
Progesterone receptor(EIA), fmol/mg
 <10 (negative) 23 (28.8%) 20 (25.0%) 0.1555 23 (48.9%)
 10–95 (Weakly positive) 15 (18.8%) 20 (25.0%) 9 (19.1%)
 96– (Strongly positive) 13 (16.3%) 27 (33.8%) 3 (6.4%)
 Not performed 29 (36.3%) 13 (16.3%) 12 (25.5%)
Type of breast surgery
 Breast conserving surgery (BCS) 27 (33.8%) 16 (20.0%) 0.0738 6 (12.8%)
 Mastectomy 53 (66.3%) 64 (80.0%) 41 (87.2%)
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cancer patients can be explained by considering the 
interval from the last childbirth (Johansson et al. 2013).
Factors such as Human Epidermal Growth Factor 
Receptor2 (HER2), Ki67 and the nuclear grade were not 
investigated in this study because these parameters were 
not routinely evaluated in the period of this case series. 
However, recurrence occurs earlier in hormone receptor-
negative cases (HER2 subtype and triple negative breast 
cancer) than in cases of the luminal subtype (Metzger-
Filho et al. 2013), and the timing of recurrence is strongly 
influenced by hormonal sensitivity (Makita et  al. 2014). 
We believe that the trend in the recurrence-free interval 
can be explained by hormonal sensitivity alone, instead of 
based on the subtype. Even if additional data were avail-
able, the results would not change regarding the chief 
influencing factor being hormone sensitivity.
Although hormonal sensitivity is routinely evaluated 
based on the immunohistochemical method, we intended 
to investigate the EIA data exclusively due to the assess-
ment to evaluate hormonal sensitivity quantitatively and 
objectively. The rates of a strongly positive PgR status 
(≥96  fmol/mg) differed based on YFLC. On the other 
Table 1 continued
Factors Case (younger than 30) Control (elder counterpart) Chi square test PABC 47 cases
Cases (%) Cases (%) P value Cases (%)
Chemotherapy
 None 24 (30.0%) 28 (35.0%) 0.3417 12 (25.5%)
 Others 5 (6.3%) 10 (12.5%) 8 (17.0%)
 CMF 33 (41.3%) 31 (38.8%) 14 (29.8%)
 Anthracycline 13 (16.3%) 8 (10.0%) 8 (17.0%)
 Anthracycline and Taxane 5 (6.3%) 2 (2.5%) 5 (10.6%)
Hormone therapy
 Ovarian function suppression ± others 11 (13.8%) 7 (8.8%) 0.0007 4 (8.5%)
 Selective estrogen receptor modulators 8 (10.0%) 28 (35.0%) 10 (21.3%)
 Others, none 61 (76.3%) 45 (56.3%) 33 (70.2%)
Radiation therapy (RT)
 Not performed 63 (78.8%) 68 (85.0%) 0.3149 42 (89.4%)
 Performed 17 (21.3%) 12 (15.0%) 5 (10.6%)
Figure 1 Progesterone receptor status in each group. Age or more recent childbirth was correlated with lower hormonal sensitivity. (YFLC years 
from the last childbirth).
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Figure 2 Concentrations of progesterone receptor on EIA. The concentrations of PgR on EIA were significantly lower in the younger than 30 group 
than in the elder counterpart group (Mann–Whitney U test p = 0.0232).
Figure 3 RFS curves in the younger than 30, Elder counterpart and PABC groups. Although the RFS curve in the younger than 30 group gradually 
decreased after 10 years, the difference between the groups was not significant.
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Table 2 Univariate and multivariate analyses
Factors Univariate analysis Cox’s proportional hasard model
Logrank test 95% CI
Cases Recurrence/died 10 year RFS (%) P value HR Lower limit Upper limit P 
value
Calendar year of surgery
 1986–1995 80 35 65.7 0.5963
 1996–2002 80 32 61.0
Family history of breast cancer
 None 138 58 64.9 0.9870
 Positive 22 9 56.9
Years from the last delivery (YFLC)
 Nulliparous 84 42 59.4 0.1208 1
 Recent (<8) 20 9 58.7 0.731 0.317 1.686 0.4618
 Past (≥8) 56 16 72.0 0.422 0.186 0.956 0.0387
 Past 56 16 72.0 0.0399
 Nulliparous/Recent 104 51 59.3
Tumor size, cm (Pathological)
 ≤5 113 43 67.0 <0.0001 1
 >5 17 13 23.5 1.426 0.520 3.912 0.4911
The number of metastatic lymph nodes
 None 78 25 74.9 <0.0001 1
 1–3 47 17 72.1 1.812 0.805 4.079 0.1512
 4–9 19 12 36.8 3.388 1.363 8.425 0.0086




45 10 83.7 0.0149 1
 Sollid-tubular carci-
noma
44 19 58.2 3.348 1.352 8.292 0.0090
 Scirrhous carcinoma 57 30 55.4 2.294 1.013 5.197 0.0465
 Special types 14 8 50.0 2.816 0.887 8.944 0.0791
Extent of tumor invasion (histological)
 Localized within gland 
or fat
149 60 65.7 0.0072 1
 Invading the skin and/
or muscle
11 7 36.4 2.455 0.888 6.787 0.0834
Lymphovascular invasion
 Absent 98 33 71.7 0.0015 1
 Present 62 34 50.6 1.883 0.966 3.696 0.0629
Estrogen receptor(EIA), fmol/mg
 <5 (negative) 61 28 62.9 0.3093
 5–21 (weakly positive) 32 12 61.1
 22– (strongly positive) 28 13 53.1
 Not performed 39 14 76.0
Progesterone receptor(EIA), fmol/mg
 <10 (negative) 43 21 56.7 0.1221
 10–95 (Weakly posi-
tive)
35 17 54.0
 96– (strongly positive) 40 14 68.8
 Not performed 42 15 75.0
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hand, the analysis of old case series and longer follow-up 
period showed that the RFS curve in the Younger than 30 
group gradually decreased, even after 10 years (Figure 3), 
whereas that in the Elder counterpart group reached a 
plateau. As for the relationship between the results for 
PgR and the prognosis, the RFS rate in the cases in which 
PgR EIA was not performed was as high as that noted in 
the cases with a strongly positive PgR status. These cases 
likely belong to an earlier stage, as the lesions were diffi-
cult to diagnose, except when performing an open biopsy, 
or were too small to obtain an adequate sample for EIA. 
PgR has been reported to be an important prognostic fac-
tor among cases of hormone sensitive breast cancer (Prat 
et al. 2013), and the PgR status was found to be related to 
the prognosis, rather than the ER status, in this study.
Whereas the number of years from the last birth was set 
at 8  years as the cutoff point calculated according to the 
ROC in this study, the prognosis of the cases within 2 years 
from the last childbirth has been reported to be worse 
(Mohle-Boetani et  al. 1988; Kroman et  al. 1997; Kroman 
and Mouridsen 2003; Nagatsuma et al. 2013). Despite the 
different cutoff points between previous and the present 
study, due to the limited number of cases in this study, the 
trends displayed in these studies were the same, and recent 
childbirth is thought to influence the prognosis of breast 
cancer. This finding is related to a report showing that 
childbirth conveys a long-term reduction in the incidence 
of breast cancer despite a transient, short-term increase in 
the incidence of such cancer (Lambe et al. 1994). Elevated 
levels of estrogens during pregnancy have been suggested 
to act as a promoter of premalignant breast cells, thus 
explaining the transient increase in risk after childbirth. It 
is probable that elevated levels of estrogens act as a stim-
ulator of malignant breast cells, which explains the tran-
sient increase in recurrent risk after childbirth. Indeed, our 
data indicate that the prognostic influence of parity dif-
fers between the patients less than 35 years of age and the 
patients 35–44 years of age. Although the 10-year RFS rate 
of parous women was 49.0%, that of nulliparous women 
was 62.9% (p = 0.0152) among the cases less than 35 years 
Table 2 continued
Factors Univariate analysis Cox’s proportional hasard model
Logrank test 95% CI




78 38 55.2 0.0189 1
 Strongly positive/Not 
performed
82 29 71.9 0.679 0.361 1.274 0.2278
Type of breast surgery
 Breast conserving 
surgery (BCS)
43 15 71.3 0.4737
 Mastectomy 117 52 61.3
Chemotherapy
 Others, none 68 23 72.9 1
 Anthracycline/Taxane/
CMF
92 44 56.8 0.0136 0.714 0.342 1.489 0.3689
Hormone therapy
 Ovarian Function Sup-
pression ± Others
18 5 67.3 0.6537
 Selective estrogen 
receptor modulators
36 15 59.5
 Others, none 106 47 64.2
Radiation therapy (RT)
 Not performed 131 54 65.6 0.2767
 Performed 29 13 53.7
Age at surgery
 Case (younger than 
30)
80 37 61.7 0.3865 0.557 0.251 1.239 0.1515
 Control (elder coun-
terpart)
80 30 65.6 1
a Category “Unilateral double cancer” was re-classified to the histological type of the larger invasive tumor.
Page 9 of 10Makita et al. SpringerPlus  (2015) 4:365 
of age. On the other hand, in the cases 35–44 years of age, 
the 10-year RFS rates of parous and nulliparous women 
were 75.4 and 77.6%, respectively. In younger women, par-
ity has an adverse effect on the prognosis and this find-
ing is related to a higher frequency of recent childbirth in 
younger women. Because childbirth conveys a long-term 
reduction in the rate of recurrence of breast cancer despite 
a transient, short-term increase in the frequency of recur-
rence, the time of 8 years from the last childbirth is consid-
ered to be the cutoff point for favorable effects rather than 
adverse effects.
The results showing that the case distribution of tumor 
size and number of lymph node metastases did not differ 
between the groups demonstrated that the effects of con-
founding factors between the two groups were success-
fully eliminated. Factors displaying differences between 
the groups included the histological type, type of breast 
surgery and YFLC. The rate of cases classified as solid-
tubular carcinoma was higher in the Younger than 30 
group than in the Elder counterpart group, and the his-
tological type was found to be an independent prognostic 
factor as well as the number of lymph node metastases 
in the multivariate analysis. Solid-tubular carcinoma 
and scirrhous carcinoma are classified as poorly differ-
entiated with a higher nuclear grade (Japanese Breast 
Cancer Society 1989) and have been reported to have a 
poor prognosis (Sakamoto 1989). It is thought that young 
patients (<35 years of age) with breast cancer are apt to 
develop poorly differentiated lesions and display more 
aggressive features (Maggard et  al. 2003; Kataoka et  al. 
2014). On the other hand, the tumor size was not found 
to be an independent prognostic factor in the current 
study. The worse prognosis of very young breast cancer 
patients is thought to be related to tumor biology, includ-
ing the histological features and hormone sensitivity.
The number of the cases treated with breast conserving 
surgery was larger in the Younger than 30 group than in 
the Elder counterpart group; however, the type of breast 
surgery was not identified to be an independent prognos-
tic factor in this study. Although age has been reported to 
be an independent prognostic factor for ipsilateral breast 
tumor recurrence (Arvold et  al. 2011), the number of 
cases of locoregional failure after surgery was almost the 
same in the two groups in the current study. Therefore, 
the difference in the type of surgery between the cases 
and controls did not necessarily influence the prognosis.
In the univariate analysis of the subgroup with 1–3 
lymph node metastases, the rates of 10-year RFS in the 
Younger than 30 and Elder counterpart groups were 59.7 
and 85.6%, respectively, and this difference was signifi-
cant (p = 0.0329). As for the case distribution in this sub-
group (24 cases in the Younger than 30 group, 23 cases in 
the Elder counterpart group), the rate of papillotubular 
carcinoma was lower and the number of cases in which a 
hormone receptor analysis was not performed was larger 
in the Younger than 30 group. The reason for not perform-
ing a hormone receptor analysis was related to the use of 
open biopsies before the diagnosis, mainly because the 
lesions were difficult to diagnose correctly in the Younger 
than 30 group. Due to the lack of hormone receptor status, 
these patients in the Younger than 30 group were treated 
with chemotherapy only and were thus treated insuffi-
ciently, although we had no data about chemotherapy-
induced amenorrhea in these cases. It is probable that the 
decreased RFS in the younger women was caused by the 
use of inadequate hormone therapy, as mentioned in other 
reports (Colleoni et  al. 2006). Another probable cause is 
that most of these cases were treated before approval was 
given for the use of luteinizing hormone releasing hor-
mone agonist (LHRHA) as adjuvant therapy.
As for family history and HBOC, there were no patients 
with BRCA mutations, and only one patient in the Younger 
than 30 group had a p53 mutation and was diagnosed with 
Li-Fraumeni syndrome (Li and Fraumeni 1969) among the 
two patients who received genetic tests. Five patients had 
more than one case of breast cancer in their family in the 
Younger than 30 group; however, no cases were observed 
in the Elder counterpart group. Over 15 years, the patients 
in the Younger than 30 group had more cases of breast 
cancer or ovarian cancer in their families, and it is prob-
able that HBOC cases were included in this group. How-
ever, such cases did not occupy the majority. Although the 
BRCA1 mutation is related to triple negative breast cancer 
(Lee et al. 2011), a family history of breast cancer did not 
influence hormonal sensitivity in this study, as three of five 
cases in the Younger than 30 group were PgR-positive.
A correlation between recent childbirth and the prog-
nosis of malignant disease has been reported and pos-
sible biological mechanisms of the adverse prognostic 
effect include immunosuppression, the hormonal milieu 
in gestation and a tumor promoting microenvironment 
post-partum (Moller et  al. 2013). However, decreased 
hormone sensitivity after childbirth is a probable chief 
cause of adverse prognostic effects. Although collected 
data about the number of years from recent childbirth 
from 207 cases was limited in this study, the breast can-
cer patients who had given birth more recently showed 
an increased rate of PgR-negative tumors in another 
report (Nagatsuma et al. 2013). The correlation between 
recent childbirth and decreased hormone sensitivity 
was demonstrated from the point of intensity evaluated 
using EIA in this study. The prognosis of the very young 
women was the same as that for their elder counterparts, 
whose tumor size was matched, and age was not an inde-
pendent prognostic factor according to the multivariate 
analysis. In conclusion, recent childbirth rather than the 
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tumor size probably influences the prognosis of breast 
cancer patients younger than 30 years of age by lowering 
hormonal sensitivity.
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